Formulation and characterization of a ten-peptide single-vial vaccine, EP-2101, designed to induce cytotoxic T-lymphocyte responses for cancer immunotherapy

Human Vaccines

Volumn 4, Issue 3, 2008, Pages 210-218

  Beebe, Melanie ^a   Qin, Mingsheng ^a   Moi, Michael ^b   Wu, Sharon ^b,d   Heiati, Hashem ^b,e   Walker, Les ^a   Newman, Mark ^a   Fikes, John ^a,c   Ishioka, Glenn Y ^a  

^a Epimmune   (United States)

^b Cardinal Health   (United States)

^c Kalypsys Inc   (United States)

^d AMGEN INC   (United States)

^e Fqubed Inc   (United States)

Author keywords

Cancer; Emulsion; Epitope; T lymphocytes; Vaccine

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; EP 2101; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; HLA A ANTIGEN; HLA DR ANTIGEN; MELANOMA ANTIGEN 2; MONTANIDE ISA 51; PADRE; PROTEIN P53; WATER OIL CREAM; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; IMMUNOLOGICAL ADJUVANT; MANNITOL; OLEIC ACID; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG FORMULATION; DRUG MIXTURE; DRUG STABILITY; IMMUNOGENICITY; INTERFERON PRODUCTION; MOUSE; NONHUMAN; PARTICLE SIZE; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; SHELF LIFE; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VACCINE PRODUCTION; VISCOSITY; ANALOGS AND DERIVATIVES; ANIMAL; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; EPITOPES, T-LYMPHOCYTE; HLA-A ANTIGENS; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; MANNITOL; MICE; MICE, TRANSGENIC; NEOPLASMS; OLEIC ACIDS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, SUBUNIT;

EID: 48249091957     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.4.3.5291     Document Type: Article

References (48)

1. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topaliet al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
2. Banchereau J, Paluka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001; 61:6451-58.
3. Lau R, Wang F, Jeffrey G, Marty V, Kuniyoshi J, Bade E, et al. Phase 1 trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001; 24:66-78.
4. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001; 98:8809-14.
5. Peterson AC, Harlin H, Gajewski TF. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant IL-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003; 21:2342-48.
6. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74:181-273.
7. Knutson ICL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 2001; 107:477-84.
8. Arlen P, Tsang KY, Marshall JL, Chen A, Steinberg SM, Poole D, et al. The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines. Cancer Immunol Immunother 2000; 49:517-29.
9. Marchand M, van Baren, N, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE3 and presented by HLA-A1. Int J Cancer 1999; 80:219-30.
10. Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004; 53:633-41.
11. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994; 1:751-61.
12. Wang, F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, et al. Phase 1 trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999; 5:2756-65.
13. + T-cell responses. J Clin Oncol 2003; 21:1562-73.
14. Slingluff CL, Yamshchikov G, Neesc P, Galavotti H, Eastham S, Engelhard VH, et al. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res 2001; 7:3012-24.
15. Vitiello A, Marchesini D, Furze J, Sherman LA, Chesnut RW. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med 1991; 173:1007-15.
16. Rongcun Y, Salazar-Onfray F, Charo J, Malmberg KJ, Evrin K, Maes H, et al. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas. J Immunol 1999; 163:1037-44.
17. Visseren MJW, Van der Burg SH, Van der Voort EIH, Brandt RMP, Schrier PI, Van der Bruggen P, et al. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int J Cancer 1997; 73:125-30.
18. Kawashima I, Hudson SJ, Tsai V, Southwood S, Takesako K, Appella E, et al. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 1998; 59:1-14.
19. Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201- binding affinity. J Immunol 2001; 167:787-96.
20. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogeniciry. Scand J Immunol 2001; 53:357-64.
21. Tangri S, Ishioka GY, Huang X, Sidney J, Southwood S, Fikes J, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med 2001; 194:833-46.
22. Zaremba S, Barzaga E, Zhu M, Soares N, Tsang KY, Schlom J. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res 1997; 57:4570-7.
23. Sette A, Keogh E, Ishioka G, Sidney J, Tangri S, Livingston B, et al. Epitope identification and vaccine design for cancer immunotherapy. Curr Opin Invest Drugs 2002; 3:132-139.
24. Sette A, Sidney J, del Guercio MF, Southwood S, Ruppert J, Dahlberg C, et al. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol 1994; 31:813-22.
25. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188:2199-204.
26. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189:753-6.
27. Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19:2666-72.
28. McKinney DM, Skvoretz R, Qin M, Ishioka G, Sette A. Characterization of an in situ IFNγ ELISA assay which is able to detect specific peptide responses from freshly isolated splenocytes induced by DNA minigene immunization. J Immunol Methods 2000; 237:105-17.
29. Alexander J, Oseroff C, Dahlberg C, Qin M, Ishioka G, Beebe M, et al. A decaepitope polypeptide primes for multiple CD8+ IFNγ and Th-lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol 2002; 168:6189-98.
30. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, et al. Phase I study of sequential vaccinations with fowpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte- macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005; 23:720-31.
31. Freund J. The mode of action of immunologic adjuvants. Bibl Tuberc 1956; 10:130-48.
32. Herbert WJ. Some investigations into the mode of action of the water-in-mineral-oil emulsion antigen adjuvants. Symp Series Immunobiol Standard 1967; 6:213-20.
33. 14C-labeled tracers. I. Mineral oil. J Pharm Sci 1970; 59:1084-8.
34. Bomford R. The adjuvant activity of fatty acid esters. The role of acyl chain length and degree of saturation. Immunology 1981; 44:187-92.
35. Edelman R. Vaccine adjuvants. Rev Infect Dis 1980; 2:370-83.
36. Kumar S, Collins W, Egan A, Yadava A, Garraud O, Blackman MJ, et al. Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun 2000; 68:2215-23.
37. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Exp Rev Vaccines 2002; 1:111-8.
38. Weber JS, Hua FL, Spears L, Marty V, Kuniyoshi C, Celis E. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freunds adjuvant in patients with resected high-risk melanoma. J Immunother 1999; 22:431-40.
39. Flies DB, Chen L.A simple and rapid vortex method for preparing antigen/adjuvant emulsions for immunization. J Immunol Methods 2003; 276:239-42.
40. Koh YT, Higgins SA, Weber JS, Kast WM. Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant. J Transl Med 2006; 4:42.
41. Gopal ESR. Principles of emulsion formation. In: Sherman P, editor. Emulsion Science. London, Academic Press, 1908: 2-75.
42. Wentworth PA, Vitiello A, Sidney J, Keogh E, Chesnut RW, Grey H, et al. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur J Immunol 1996; 26:97-101.
43. Smith CL, Mirza F, Pasquetto V, Tscharke DC, Palmowski MJ, Dunbar PR, et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 2005; 175:8431-7.
44. Rodriguez F, Harkins S, Slifka MK, Whitton JL. Immunodominance in virus-induced CD8(+) T-cell responses is dramatically modified by DNA immunization and is regulated by gamma interferon. J Virol 2002; 76:4251-9.
45. An LL, Whitton JL. A multiple minigene vaccine containing B cell, CTL and Th epitopes from several mictobes, induces appropriate responses in vivo, and confers protection against more than one pathogen. J Virol 1997; 71:2292-302.
46. Hanke T, Neumann VC, Blanchard TK, Sweeney P, Hill AVS, Smith GL, et al. Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine 1999; 17:589-96.
47. + T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun 2003; 3:15.
48. Chianese Bullock KA, Pressley J, Garbee C, Hibbitts S, Murphy C, Yamshchikov G, et al. MAGE-A1-, MAGE-A10- and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and Montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma. J Immunol 2005; 174:3080-6.